Rexomun (ertumaxomab) / Trion Pharma - LARVOL DELTA

T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis. (PubMed, Cancer Treat Rev) - "Of these studies, 21 publications were included for meta-analysis, focussing on four TCEs: catumaxomab, ertumaxomab, tebentafusb, and MDX-H210. Cytokine Release Syndrome (CRS) is potentially being under-reported due to challenges of differentiation of CRS from other inflammatory mediated constituent symptoms, although Fc-independent TCEs were linked to lower inflammatory toxicity. The review highlights TCE-dependent toxicity profiles and highlights key features that may ameliorate TCE tolerance."

Journal • Retrospective data • Review • Inflammatory Bowel Disease • Oncology • Solid Tumor • CD40

Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment. (PubMed, Curr Drug Deliv) - "There has been significant worldwide progress in the development of monoclonal antibodies (mAbs) since 1986, when the first therapeutic mAb, Orthoclone OKT3, became commercially available...This review focuses on the therapeutic applications, mechanistic insights, characteristics, safety aspects, and adverse events of mAbs like trastuzumab, bevacizumab, pertuzumab, ertumaxomab, and atezolizumab in breast cancer treatment. The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multispecific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer